Gilead and Galapagos closed their global license and collaboration for filgotinib, a selective JAK1 inhibitor in Phase 3 for rheumatoid arthritis. Galapagos received $725M upfront ($300M license fee + $425M equity investment giving Gilead 14.75% stake at EUR58/share). Galapagos eligible for up to $1.35B in milestones plus tiered royalties starting at 20%, with co-promotion profit splits in select territories.